BREAKING
Nexxen Q4 FY26 Earnings Results 14 hours ago Daktronics Q3 FY26 Earnings Results 15 hours ago Earnings Summary: SmartRent Returns to Growth in Q4FY25, Achieves Positive EBITDA. 17 hours ago Abercrombie & Fitch Q4 2025 Earnings Results 18 hours ago AutoZone (AZO) Q2 2026 earnings decline despite 8% sales growth 2 days ago Best Buy 4Q 2026: Earnings Analysis 2 days ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 3 days ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 3 days ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 3 days ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 6 days ago Nexxen Q4 FY26 Earnings Results 14 hours ago Daktronics Q3 FY26 Earnings Results 15 hours ago Earnings Summary: SmartRent Returns to Growth in Q4FY25, Achieves Positive EBITDA. 17 hours ago Abercrombie & Fitch Q4 2025 Earnings Results 18 hours ago AutoZone (AZO) Q2 2026 earnings decline despite 8% sales growth 2 days ago Best Buy 4Q 2026: Earnings Analysis 2 days ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 3 days ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 3 days ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 3 days ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 6 days ago
ADVERTISEMENT
Market News

Earnings preview: Medical devices to drive Abbott Q1 results

Abbott Laboratories (NYSE: ABT) is scheduled to report its earnings results for the first quarter of 2019 on Wednesday before the market opens. The results could be benefited by the segments Medical Devices, Established Pharmaceuticals, and Diagnostics as well as Nutrition that are likely to yield a greater return for the quarter. The company has […]

April 16, 2019 2 min read
Market News

Abbott Laboratories (NYSE: ABT) is scheduled to report its earnings results for the first quarter of 2019 on Wednesday before the market opens. The results could be benefited by the segments Medical Devices, Established Pharmaceuticals, and Diagnostics as well as Nutrition that are likely to yield a greater return for the quarter. The company has […]

· April 16, 2019

Abbott Laboratories (NYSE: ABT) is scheduled to report its earnings results for the first quarter of 2019 on Wednesday before the market opens. The results could be benefited by the segments Medical Devices, Established Pharmaceuticals, and Diagnostics as well as Nutrition that are likely to yield a greater return for the quarter.

The company has been consistently investing in its research and development for bringing out a new product pipeline that could achieve high productive and strong growth trends for the first quarter. The diagnostic instruments Alinity and infectious disease testing could drive Diagnostics sales higher. The cardiac mapping, ablation catheters, Structural Heart and Diabetes Care could drive sales of Medical Devices higher.

Abbott diagnostics center
Image Courtesy: Abbott / Facebook page

Analysts expect Abbott’s earnings to increase by 3.40% to $0.61 per share and revenue to rise by 1.10% to $7.47 billion for the first quarter. In comparison, during the previous year quarter, the company reported a profit of $0.59 per share on revenue of $7.39 billion.

Investors remained confused whether Abbott will beat the analysts’ expectations as the company’s history suggested it exceeded two times in the last four quarters while coming in line for the balance.

For the fourth quarter, the company swung to a profit from a loss last year, driven by a decline in tax expense. Worldwide sales increased 2.3% on a reported basis and 6.4% on an organic basis, helped by higher sales from Medical Devices and Diagnostics businesses.

For the first quarter, Abbott had expected earnings from continuing operations in the range of $0.25 to $0.27 per share and adjusted earnings to be $0.60 to $0.62 per share range. For the full year 2019, the company had predicted organic sales growth of 6.5% to 7.5% and earnings from continuing operations in the range of $1.80 to $1.90 per share. Adjusted earnings from continuing operations were anticipated to be in the range of $3.15 to $3.25 per share for the full year.

Shares of Abbott opened higher on Tuesday and is trading in the green territory. The stock has risen over 32% in the past year and over 10% in the past three months.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!